Literature DB >> 15199458

Oral anticoagulant initiation: rationale for the use of warfarin dosing nomograms.

Mark Andrew Crowther1.   

Abstract

Oral anticoagulants prevent thrombosis however they are associated with bleeding. The risk of both bleeding and thrombosis is increased when the International Normalized Ratio (INR) is outside the desired therapeutic range. Hence, oral anticoagulants should be administered with the intention of maximizing the "time within the therapeutic range." The frequency of INR values outside this range can be decreased by (1) warfarin initiation algorithms that guide initial therapy and (2) use of computerized systems to guide chronic warfarin therapy. This article reviews these techniques.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15199458     DOI: 10.1055/s-2003-44461

Source DB:  PubMed          Journal:  Semin Vasc Med        ISSN: 1528-9648


  3 in total

1.  Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model.

Authors:  Johanna H H Van Geest-Daalderop; Barbara A Hutten; Nathalie C V Péquériaux; Marcel Levi; Augueste Sturk
Journal:  J Thromb Thrombolysis       Date:  2008-02-13       Impact factor: 2.300

2.  Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

Authors:  Ryuhei Saito; Kenji Takeda; Kayo Yamamoto; Akihiko Nakagawa; Hirofumi Aoki; Kosuke Fujibayashi; Minoru Wakasa; Atsushi Motoyama; Mizuho Iwadare; Ryoko Ishida; Nakaba Fujioka; Taketsugu Tsuchiya; Hironobu Akao; Yasuyuki Kawai; Michihiko Kitayama; Kouji Kajinami
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  A multi-factorial analysis of response to warfarin in a UK prospective cohort.

Authors:  Stephane Bourgeois; Andrea Jorgensen; Eunice J Zhang; Anita Hanson; Matthew S Gillman; Suzannah Bumpstead; Cheng Hock Toh; Paula Williamson; Ann K Daly; Farhad Kamali; Panos Deloukas; Munir Pirmohamed
Journal:  Genome Med       Date:  2016-01-06       Impact factor: 11.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.